Genome Engineering

Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

CRISPR vs. Base Editing vs. Prime Editing: Which Genome Editing Technology Is Best?

Pharma's Almanac

Epigenome Editing

Rewriting Gene Expression Without Rewriting DNA: The Emerging Field of Epigenetic Editing

David Alvaro, Ph.D.

Pharma's Almanac

CVD Gene Editing

Editing Risk: Gene Targets for Lifelong Cardiovascular Disease Prevention

David Alvaro, Ph.D.

Pharma's Almanac

RNA Polymerase

Smarter Polymerases, Cleaner Transcripts, Better RNA

Jing Zhu, Ph.D.

Recipharm Advanced Bio

CRISPR

Integrated Capabilities Enable Faster Development of Effective CRISPR Therapies

Jessica Madigan; Amanda Haas

BIOVECTRA

Gene Editing

A Universal Strategy for Rare Diseases? Researchers Unveil a Mutation-Agnostic Editor

David Alvaro, Ph.D.

Pharma's Almanac

ssDNA

Leveraging the Therapeutic Potential of Single-Stranded DNA

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Gene Editing

What are the key ethical and regulatory considerations as gene editing technologies advance toward widespread clinical use?

Pharma's Almanac

Xenotransplantation

CRISPR-Edited Pig Organs and the Promise of Xenotransplantation

David Alvaro, Ph.D.

Pharma's Almanac

Gene Therapy

Gene Therapy at 30: Milestones, Setbacks, and a Path Forward

Cynthia A. Challener, Ph.D.

Pharma's Almanac

RNA

Beyond mRNA Vaccines: The Expanding World of RNA-Based Therapeutics

David Alvaro, Ph.D.

Pharma's Almanac

HTS

The High-Throughput Screening Transformation in Modern Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

Small Biotechs

Five Small Biotechs to Watch: March 2025

David Alvaro, Ph.D.

Pharma's Almanac

CRISPR

The Groundbreaking Potential of CRISPR Gene Editing

Olivia Newton-John Cancer Research Institute

Gene Editing

MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing

Tom Adie, Ph.D.; Elena Stoyanova, Ph.D.

Touchlight

dbDNA

Revolutionizing the Genetic Medicine Landscape with Enzymatic DNA

Jill Makin

Touchlight

Cell Therapy

Creating Efficiencies in Engineered Cell Therapy Development with Comprehensive Electroporation Support

Sarah Meeks, Ph.D.

MaxCyte

Lipid Nanoparticle Development

Lipid Technology for Delivery of Gene-Editing Therapies

Stephen Burgess, Ph.D.

Croda Pharma